Skip to content

BIND, founded in 2007, was a clinical-stage nanomedicine platform company developing Accurins®, a novel targeted and programmable class of therapeutics designed to target specific cells or tissues and concentrate a therapeutic payload at the site of disease. BIND Therapeutics raised a $70M+ IPO in 2013 and the company’s assets were acquired by Pfizer in 2016.

Latest News from BIND Therapeutics